Recent advances in lipopolysaccharide-based glycoconjugate vaccines
<strong>Introduction</strong> The public health burden caused by pathogenic Gram-negative bacteria is increasingly prominent due to antimicrobial resistance. The surface carbohydrates are potential antigens for vaccines against Gram-negative bacteria. The enhanced immunogenicity of the O...
| Main Authors: | , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Taylor and Francis
2021
|
| _version_ | 1797073435055095808 |
|---|---|
| author | Zhu, H Rollier, CS Pollard, AJ |
| author_facet | Zhu, H Rollier, CS Pollard, AJ |
| author_sort | Zhu, H |
| collection | OXFORD |
| description | <strong>Introduction</strong>
The public health burden caused by pathogenic Gram-negative bacteria is increasingly prominent due to antimicrobial resistance. The surface carbohydrates are potential antigens for vaccines against Gram-negative bacteria. The enhanced immunogenicity of the O-specific polysaccharide (O-SP) moiety of LPS when coupled to a carrier protein may protect against bacterial pathogens. However, because of the toxic lipid A moiety and relatively high costs of O-SP isolation, LPS has not been a popular vaccine antigen until recently.
<br>
<strong>Areas covered</strong>
In this review, we discuss the rationales for developing LPS-based glycoconjugate vaccines, principles of glycoconjugate-induced immunity, and highlight the recent developments and challenges faced by LPS-based glycoconjugate vaccines.
<br>
<strong>Expert opinion</strong>
Advances in LPS harvesting, LPS chemical synthesis, and newer carrier proteins in the past decade have propelled LPS-based glycoconjugate vaccines toward further development, through to clinical evaluation. The development of LPS-based glycoconjugates offers a new horizon for vaccine prevention of Gram-negative bacterial infection. |
| first_indexed | 2024-03-06T23:22:06Z |
| format | Journal article |
| id | oxford-uuid:6914b489-a8dd-4888-86e1-9183b74dded1 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:22:06Z |
| publishDate | 2021 |
| publisher | Taylor and Francis |
| record_format | dspace |
| spelling | oxford-uuid:6914b489-a8dd-4888-86e1-9183b74dded12022-03-26T18:49:05ZRecent advances in lipopolysaccharide-based glycoconjugate vaccinesJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:6914b489-a8dd-4888-86e1-9183b74dded1EnglishSymplectic ElementsTaylor and Francis2021Zhu, HRollier, CSPollard, AJ<strong>Introduction</strong> The public health burden caused by pathogenic Gram-negative bacteria is increasingly prominent due to antimicrobial resistance. The surface carbohydrates are potential antigens for vaccines against Gram-negative bacteria. The enhanced immunogenicity of the O-specific polysaccharide (O-SP) moiety of LPS when coupled to a carrier protein may protect against bacterial pathogens. However, because of the toxic lipid A moiety and relatively high costs of O-SP isolation, LPS has not been a popular vaccine antigen until recently. <br> <strong>Areas covered</strong> In this review, we discuss the rationales for developing LPS-based glycoconjugate vaccines, principles of glycoconjugate-induced immunity, and highlight the recent developments and challenges faced by LPS-based glycoconjugate vaccines. <br> <strong>Expert opinion</strong> Advances in LPS harvesting, LPS chemical synthesis, and newer carrier proteins in the past decade have propelled LPS-based glycoconjugate vaccines toward further development, through to clinical evaluation. The development of LPS-based glycoconjugates offers a new horizon for vaccine prevention of Gram-negative bacterial infection. |
| spellingShingle | Zhu, H Rollier, CS Pollard, AJ Recent advances in lipopolysaccharide-based glycoconjugate vaccines |
| title | Recent advances in lipopolysaccharide-based glycoconjugate vaccines |
| title_full | Recent advances in lipopolysaccharide-based glycoconjugate vaccines |
| title_fullStr | Recent advances in lipopolysaccharide-based glycoconjugate vaccines |
| title_full_unstemmed | Recent advances in lipopolysaccharide-based glycoconjugate vaccines |
| title_short | Recent advances in lipopolysaccharide-based glycoconjugate vaccines |
| title_sort | recent advances in lipopolysaccharide based glycoconjugate vaccines |
| work_keys_str_mv | AT zhuh recentadvancesinlipopolysaccharidebasedglycoconjugatevaccines AT rolliercs recentadvancesinlipopolysaccharidebasedglycoconjugatevaccines AT pollardaj recentadvancesinlipopolysaccharidebasedglycoconjugatevaccines |